Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C (Q34914880)

5 August 2017

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

Abdus S Wahed

7

0 references

Nezam Afdhal

object named as

Nezam H Afdhal

9

0 references

K. Rajender Reddy

6

object named as

K Rajender Reddy

1 reference

5 August 2017

Roy L Hawke

1

1 reference

5 August 2017

Sarah J Schrieber

2

1 reference

5 August 2017

Tedi A Soule

3

1 reference

5 August 2017

Zhiming Wen

4

1 reference

5 August 2017

Philip C Smith

5

1 reference

5 August 2017

Steven H Belle

8

1 reference

5 August 2017

Victor J Navarro

10

1 reference

5 August 2017

Josh Berman

11

1 reference

5 August 2017

Qi-Ying Liu

12

1 reference

5 August 2017

Edward Doo

13

1 reference

5 August 2017

Michael W Fried

14

1 reference

5 August 2017

SyNCH Trial Group

15

1 reference

5 August 2017

language of work or name

1 reference

19 October 2009

1 reference

The Journal of Clinical Pharmacology

5 August 2017

1 reference

5 August 2017

50

1 reference

5 August 2017

4

1 reference

5 August 2017

434-449

1 reference

Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Peginterferon and ribavirin for chronic hepatitis C.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Silymarin treatment of viral hepatitis: a systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Use of complementary and alternative medicine in patients with liver disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Milk thistle (Silybum marianum) for the therapy of liver disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

8 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Silibinin protects mice from T cell-dependent liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009347475

Comparative bioavailability of silibinin in healthy male volunteers.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086763

Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1

26 October 2018

1 reference

12 December 2020

Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process

1 reference

12 December 2020

Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study

1 reference

12 December 2020

Use of the Romanian product Silimarina in the treatment of chronic liver diseases

1 reference

12 December 2020

[Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]

1 reference

12 December 2020

Comparative bioavailability of Silipide, a new flavanolignan complex, in rats

1 reference

12 December 2020

Comparative pharmacokinetics of silipide and silymarin in rats

1 reference

12 December 2020

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract

1 reference

12 December 2020

Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation

1 reference

12 December 2020

Identifiers

DOI

10.1177/0091270009347475

1 reference

5 August 2017

1 reference

5 August 2017

1 reference